Institute of Pharmacology, University of Bern, Switzerland.
Adv Exp Med Biol. 2012;750:239-61. doi: 10.1007/978-1-4614-3461-0_18.
It was a long way from the use of hyperimmune animal sera for the treatment of toxin-producing infections to the production of polyclonal, polyspecific human immunoglobulin preparations and the use of NAbs as therapeutic tools for autoimmune and inflammatory diseases. Some highlights of the development of knowledge in blood fractionation techniques, basic science and clinical wisdom are reviewed in this chapter. Proudly we mention the outstanding contribution of Swiss scientists and clinicians in the development of IVIG as clinical tool for some otherwise untreatable diseases or taking advantage of its low adverse event profile in long-term treatment of other chronic autoimmune and inflammatory diseases. This chapter summarizes some of the characteristics and the effects in humans of NAbs which are present in IgG concentrates. We call attention to the fact that the human data remain, at least in part, incomplete, among others because even with the most efficient large-scale techniques available not more than approximately 50% of the total IgG in plasma can be fractionated into an immunoglobulin G concentrate.
从使用高免疫动物血清治疗产毒感染，到生产多克隆、多特异性人免疫球蛋白制剂，以及将 NAb 用作治疗自身免疫和炎症性疾病的工具，这一过程经历了漫长的发展历程。本章回顾了血液分离技术、基础科学和临床实践方面知识发展的一些亮点。我们自豪地提到了瑞士科学家和临床医生在 IVIG 发展方面的杰出贡献，将其作为一些原本无法治疗的疾病的临床工具，或者利用其在长期治疗其他慢性自身免疫和炎症性疾病时的低不良事件谱的优势。本章总结了 IgG 浓缩物中存在的 NAb 的一些特性和对人类的影响。我们提请注意一个事实，即人类数据仍然存在不完整的情况，这至少部分是因为，即使使用最有效的大规模技术，也只能将血浆中大约 50%的总 IgG 分离成免疫球蛋白 G 浓缩物。
